ORIGINAL RESEARCH

Relationship Between the Ratio of Acceleration Time/Ejection Time and Mortality in Patients With High-Gradient Severe Aortic Stenosis

Alexandre Altes, MD; Nicolas Thellier, MD; Yohann Bohbot, MD, PhD; Anne Ringle Griguer, MD, PhD; Stéphane Verdun, PhD; Franck Levy, MD; Anne Laure Castel, MD; François Delelis, MD; Amandine Mailliet, RN; Christophe Tribouilloy, MD, PhD; Sylvestre Maréchaux, MD, PhD

BACKGROUND: The ratio of acceleration time/ejection time (AT/ET) is a simple and reproducible echocardiographic parameter that integrates aortic stenosis severity and its consequences on the left ventricle. No study has specifically assessed the prognostic impact of AT/ET on outcome in patients with high-gradient severe aortic stenosis (SAS) and no or mild symptoms. We sought to evaluate the relationship between AT/ET and mortality and determine the best predictive AT/ET cutoff value in these patients.

METHODS AND RESULTS: A total of 353 patients (median age, 79 years; 46% women) with high-gradient (mean pressure gradient ≥40 mm Hg and/or aortic peak jet velocity ≥4 m/s) SAS, left ventricular ejection fraction ≥50%, and no or mild symptoms were studied. The impact of AT/ET ≤0.35 or >0.35 on all-cause mortality was retrospectively studied. During a median follow-up of 39 (25th–75th percentile, 23–62) months, 70 patients died. AT/ET >0.35 was associated with a considerable increased mortality risk after adjustment for established prognostic factors in SAS under medical and/or surgical management (adjusted hazard ratio [HR], 2.54; 95% CI, 1.47–4.37; P<0.001) or conservative management (adjusted HR, 3.29; 95% CI, 1.70–6.39; P<0.001). Moreover, AT/ET >0.35 improved the predictive performance of models including established risk factors in SAS with better global model fit, reclassification, and discrimination. After propensity matching, increased mortality risk persisted when AT/ET >0.35 (adjusted HR, 2.10; 95% CI, 1.12–3.90; P<0.001).

CONCLUSIONS: AT/ET >0.35 is a strong predictor of outcome in patients with SAS and no or only mild symptoms and identifies a subgroup of patients at higher risk of death who may derive benefit from earlier aortic valve replacement.

Key Words: aortic stenosis ■ echocardiography ■ ejection dynamic parameters ■ outcome

The sole optimal treatment for patients with severe aortic stenosis (SAS) is aortic valve replacement (AVR). Although symptomatic SAS is a class I indication for AVR, the optimal timing of intervention in patients with asymptomatic SAS is a matter of paramount importance.1 Hence, several echocardiographic indexes have been proposed to refine the prognostic assessment of patients with SAS, including the severity of valve narrowing (aortic peak jet velocity [Vmax] >5 or 5.5 m/s, according to either European Society of Cardiology or American College of Cardiology/American Heart Association guidelines) and/or left ventricular (LV) systolic function impairment (LV ejection fraction ≤50%, low flow status, and impairment of global longitudinal strain [GLS] <15%).2–5 LV ejection dynamic parameters have received in the past few years renewed attention in
the assessment of native aortic stenosis (AS).6 Indeed, the ratio of acceleration time/ejection time (AT/ET) is a simple and reproducible echocardiographic parameter that integrates AS severity and its consequences on the LV.7,8 Previous reports have suggested that increased AT/ET may be associated with adverse outcome in patients with moderate AS or SAS or with discordant grading, that is those with low-gradient SAS, and preserved LVEF, with divergent cutoff values among studies and regardless of symptomatic status.9–12 Notwithstanding, no study has specifically assessed the relationship between AT/ET and mortality in the population of patients with “classic” (ie, high-gradient) SAS and no or only mild symptoms. Hence, the objectives of this bicenter study were (1) to evaluate the prognostic impact of AT/ET on mortality in a cohort of patients with high-gradient SAS with preserved LVEF and no or mild symptoms; (2) to establish a prognostic cutoff value of AT/ET associated with mortality risk; and (3) to assess the incremental prognostic value of AT/ET over established risk factors in SAS.

**METHODS**

The data that support the findings of this study are available from the corresponding author on reasonable request.

**Patient Population**

Between 2012 and 2019, patients of at least 18 years of age, diagnosed with high-gradient (defined as mean aortic pressure gradient [MPG] ≥40 mm Hg and/or Vmax ≥4 m/s) SAS (defined as aortic valve area [AVA] ≤1 cm² and/or AVA normalized to body surface area ≤0.6 cm²/m²) and no or only mild AS related symptoms who attended the heart valve clinics of 2 tertiary hospitals in France (Lille and Amiens), were prospectively enrolled in the present ancillary study from a larger registry.9 The following patients were excluded: (1) patients with more than mild aortic and/or mitral regurgitation; (2) patients with prosthetic valves, congenital heart disease (with the exception of bicuspid aortic valves), supravalvular or subvalvular AS, or dynamic LV outflow tract obstruction; (3) those with past or current symptoms of New York Heart Association class III to IV heart failure; (4) those with angina or syncope; and (5) patients who refused to participate in the study. Clinical and demographic characteristics were collected at baseline. The Charlson comorbidity index, summing the patient’s individual comorbidities, was calculated.13 Patients were deemed as having coronary artery disease if they had a documented history of acute coronary syndrome, coronary artery disease previously documented by coronary angiography, or a history of coronary revascularization. Institutional review board approval was obtained. The study was approved by our institutional review committee, and the subjects gave informed consent.

**Echocardiography**

All patients underwent a comprehensive Doppler-echocardiography study, using commercially available...
ultrasound systems by experienced echocardiographers. Echocardiograms were stored in Digital Imaging and Communications in Medicine format to allow subsequent offline analysis. Aortic flow was recorded using continuous-wave Doppler, by imaging and nonimaging transducers, systematically in several acoustic windows (apical 5-chamber, right parasternal, suprasternal, and epigastric). The view identifying the highest velocities was used to determine Vmax and MPG. Pressure gradients were calculated using the simplified Bernoulli equation. Pulsed Doppler LV outflow tract velocity was recorded in the apical 5-chamber view with the sample volume at 5 mm proximal from the plane of the aortic valve. Alignment of both pulsed and continuous-wave Doppler was optimized to be parallel with flow. Doppler recordings were performed at a sweep speed of 100 mm/s. AT was defined as time from the start to the peak of flow through the valve by continuous-wave Doppler. ET was defined from aortic valve opening to aortic valve closure. The AT/ET ratio was then calculated (Figure 1). The interobserver reproducibility of AT/ET was good in a previous report from our group, with an intraclass correlation coefficient of 0.90 (95% CI, 0.78–0.96) and a coefficient of variation of 7.3%.9 Similarly, Einarsen et al reported an excellent intraobserver reproducibility for AT/ET, with an intraclass coefficient at 0.98 (95% CI, 0.76–0.94; bias, −0.8%). Conventional echocardiographic measurements were performed according to current European Association of Cardiovascular Imaging/American Society of Echocardiography guidelines. When patients were in sinus rhythm, 3 cardiac cycles were averaged for all measures. For patients in atrial fibrillation (AF), 5 cardiac cycles were averaged.

### Treatment Decision and Follow-Up

After the initial medical management, treatment was conservative or surgical, as deemed appropriate by the patient’s personal physician. Most patients were followed up by clinical consultation and echocardiography in the outpatient clinics of the 2 tertiary centres. The others were followed up in public hospitals or private practices by referring cardiologists working together with the tertiary centres. Information on follow-up was retrospectively obtained. Events were ascertained by direct patient interview and clinical examination and/or by repeated follow-up letters, questionnaires, and telephone calls to physicians, patients, and (if necessary) next of kin. Medical reports and death certificates were consulted for attribution of causes of death. The main outcome measure of interest was overall mortality after diagnosis, starting at baseline echocardiography, regardless whether there was AVR. Overall mortality was also analyzed in the subgroup of patients not undergoing AVR during the first 3 months after baseline echocardiography (conservatively managed group). In this case, the follow-up time during which events were collected for this end point was between diagnosis and either AVR (if performed) or last follow-up. Clinical decisions on medical management and referral for surgery were made by the heart team with the approval of the patient’s cardiologist, in accordance with practice guidelines.

### Statistical Analysis

Quantitative data are presented as mean±SD or median (25th–75th percentile). Qualitative data are presented as absolute numbers and percentages. Pearson coefficient correlations were used to evaluate the relationship between AT, ET, AT/ET, and heart rate. Patients...
were stratified by AT/ET >0.35 or ≤0.35, according to the threshold identified with the use of maximally selected rank statistics. Maximally selected rank statistics allow the estimation or evaluation of a simple cut point that provides the classification of observations into 2 groups (ie, distinction of a low- and a high-risk group in survival studies) by a continuous or ordinal predictor variable (herein, AT/ET). To this effect, the maxstat.test() function from the maxstat R package 0.7-25 was used (method="HL", method="LogRank"). The Pearson χ² statistic or Fisher exact test was used to examine the associations between the 2 groups and baseline categorical variables. Individual differences for continuous variables were compared using Mann-Whitney U tests. The intraclass correlation was used to express GLS variability between the 2 software platforms, with the same observer performing the analysis with at least a 6-month delay between the 2 analyses (GE EchoPac and Tomtec LV Autostrain). The intraclass correlation coefficient estimates and their 95% CIs were calculated on the basis of a single rater/measurement, absolute-agreement, 2-way fixed-effects model. Event rates of the overall population and of the 2 groups were estimated according to the Kaplan-Meier method and compared with 2-sided log-rank tests. Median follow-up time was obtained using the reverse Kaplan-Meier method. Univariate and multivariable analyses of time to events were performed using Cox proportional-hazards models. Models were fit using the coxph() function from the survival R package 3.2-13.17 Penalized smoothing splines were used to illustrate the association of AT/ET and the risk for mortality during follow-up. We did not use model building techniques; covariates were entered in the models that were considered of potential prognostic impact on an epidemiologic basis. Models were adjusted for age, sex, Charlson comorbidity index (not including age), systolic blood pressure (SBP), history of AF, LVEF, Vmax, LV-SVi, and AVR. No multiple imputation was performed for multivariable model building process because of the low number of missing data for these covariates (<2.5%). The effect of AVR on outcome was analyzed as a time-dependent covariate using the entire follow-up.18 The proportional hazards assumption was confirmed using statistics and graphs based on the Schoenfeld residuals. For continuous variables, the assumption of linearity was assessed by plotting residuals against independent variables. To verify the stability of the results, and any biases generated by overfitting, the Harrell C-statistics evaluating the accuracy of risk prediction for the multivariable models and the hazard ratio (HR) coefficients with their 95% CIs for AT/ET >0.35 were estimated by the bootstrapping technique with 1000 samples (boot package 1.3-28 in R).19 The Harrell C-statistics were also calculated for the multivariable models using the k-fold cross-validation technique (k=5, 100 iterations), which lead to an estimate less sensitive to overfitting. To assess the incremental prognostic value of AT/ET over clinical and echocardiographic parameters known of prognostic importance in asymptomatic SAS, nested regression models were constructed and changes in χ² value were calculated. Integrated discrimination improvement and net reclassification improvement were determined to further describe the added utility of AT/ET when added to the multivariable models. Integrated discrimination improvement measures the new model’s ability to improve integrated sensitivity without compromising integrated specificity. Net reclassification improvement measures the appropriateness of patient reclassification on the basis of the probability of death at selected time points. Net reclassification improvement and integrated discrimination improvement were computed at 36 months using the R package survIDINRI 1.1-1.20 We aimed also at identifying if there was a difference in the prognostic value of AT/ET ≤0.35 or >0.35 in prespecified subgroups of patients (aged >80 or ≤80 years, sex status, body surface area >1.80 m² or ≤1.80 m², New York Heart Association functional class I versus II, history of AF versus no history of AF, documented coronary artery disease versus no documented coronary artery disease, Vmax ≥5 m/s versus <5 m/s, MPG ≥50 mm Hg versus <50 mm Hg, AVA ≥0.75 cm² versus <0.75 cm², LVEF >60% versus ≤60%, LV-SVi >35 mL/m² versus ≤35 mL/m², and LV hypertrophy versus no LV hypertrophy). Hence, a first-order interaction term (between AT/ET ≤0.35 or >0.35 and categories of subgroups, corresponding to the product of these 2 variables) was systematically included in a Cox multivariable model including AT/ET ≤0.35 or >0.35 and the categories of each subgroup of patients in the whole cohort of patients. A significant interaction was considered in case of a P value for the interaction variable <0.05. Univariable Cox models testing the impact of AT/ET ≤0.35 or >0.35 on mortality were obtained thereafter in each category of the subgroups of patients. Sensitivity analysis was also conducted in a propensity-matched sample to compare the occurrence of mortality during follow-up between patients with AT/ET >0.35 and ≤0.35. Propensity matching was performed on the basis of 1-to-1 nearest neighbor matching with a greedy matching algorithm and a caliper width of 0.2 (Matchit package 4.2.0 in R).21 The following covariates were used to assign the propensity score: age, sex, Charlson comorbidity index (not including age), SBP, history of AF, New York Heart Association functional class, LVEF, Vmax, LV-SVi, AVA, and LV mass index. Standardized mean differences before and after matching were estimated to assess the quality of the propensity score matching procedure. Standardized mean differences <0.2
after matching were considered as indicators of adequate balance and thus sufficient bias reduction. The quality of the matching was visually assessed by the distribution of propensity scores (jitter plot of the distance measure, QQ plots, and histograms of propensity score density for observations before and after matching). To account for the matching, we used a Cox model with a random effect for the matched pairs (shared frailty model, using a \( \gamma \) distribution). All \( P \) values are the results of 2-tailed tests. For all analyses, \( P<0.05 \) was considered statistically significant. Data were analyzed with R version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria), GraphPad Prism (GraphPad Software, La Jolla, CA), and SPSS version 20.0 (IBM, Armonk, NY).

**RESULTS**

**Study Population**

A total of 353 patients (women, 46%; median age, 79 years) were included in the present study. Their baseline characteristics are depicted in Table 1. Median AT/ET was 0.35 (25th–75th percentile, 0.32–0.39). A total of 139 (39%) patients used \( \beta \) blockers at time of examination. No differences were observed for use of \( \beta \) blockers between patients with AT/ET >0.35 versus \( \leq 0.35 \) (\( P=0.453 \)). ET was longer for patients using \( \beta \) blockers (320 [288–345] versus 300 [281–323] ms; \( P=0.001 \)). However, AT (110 [96–123] versus 104 [93–120] ms; \( P=0.108 \)) and AT/ET (0.35 [0.31–0.39] versus 0.35 [0.32–0.39]; \( P=0.586 \)) were similar for patients under \( \beta \) blockers or not. An inverse linear relationship was observed between AT or ET and heart rate (\( r=-0.19 \) [\( P<0.001 \)] and \( r=-0.32 \) [\( P<0.001 \)], respectively). In contrast, no relationship was found between AT/ET and heart rate (\( r=0.06 \); \( P=0.284 \)). AT/ET was slightly higher in women, but this difference did not reach statistical significance (0.36 [0.32–0.39] versus 0.35 [0.31–0.38]; \( P=0.072 \)). Patients with low flow exhibited lower ET than those with normal flow (290 [262–302] ms versus 309 [285–334] ms; \( P=0.001 \)). Patients were stratified by AT/ET \( \leq 0.35 \) or >0.35. The differences in AT/ET between these 2 groups were driven by AT (\( P<0.001 \)), whereas distribution of ET was similar (\( P=0.647 \); Figure S1). Briefly, patients with AT/ET >0.35 had similar demographic and clinical characteristics than patients with AT/ET \( \leq 0.35 \), except for a lower SBP. For echocardiographic parameters, patients with AT/ET >0.35 shared features of more severe AS compared with other patients, with lower AVA, AVA indexed to body surface area, and dimensionless index and higher MPG and Vmax. Significant, but weak, positive linear relationships were observed between AT/ET and transaortic mean gradient or Vmax (\( r=0.30 \) [\( P<0.001 \)] and \( r=0.22 \) [\( P<0.001 \)], respectively). Last, patients with AT/ET >0.35 had higher LV mass and lower LV ejection fraction and GLS magnitude.

**Clinical Management and Follow-Up**

Median follow-up time was 39 (25th–75th percentile, 23–62) months. Overall mortality at 36 months was 19%. Among the 238 patients (67%) who underwent AVR, 31 had at least one associated coronary artery bypass graft at the time of surgery. A total of 154 (65%) patients underwent surgical AVR and 84 (35%) patients underwent transcatheter AVR (Table S1). Seventy patients (20%) died during the entire follow-up, 52 (74%) before AVR and 18 (26%) after AVR.

**Outcome With Conservative and/or Surgical Management**

On univariate analysis, AT/ET as a continuous variable (per increment of 0.01) was associated with increased risk of mortality (HR, 1.06; 95% CI, 1.06–1.11; \( P=0.018 \)). In contrast, no relationship was found between AT or ET (per increment of 10 ms) taken aside and mortality risk (HR, 1.08; 95% CI, 0.97–1.21; \( P=0.158 \); and HR, 1.01; 95% CI, 0.96–1.07; \( P=0.698 \)). The shape of the relationship between AT/ET as a continuous variable and risk for mortality during follow-up was estimated using spline functions for AT/ET (Figure 2). Optimal cut point of AT/ET for predicting mortality was obtained by the use of maximally selected rank statistics method (Figure 3). By statistical coincidence, the optimal threshold was observed at 0.35, which corresponded to the median value of AT/ET in this study population. The primary end point occurred during the entire follow-up in 26 patients (14%) with AT/ET \( \leq 0.35 \) and 44 patients (26%) with AT/ET >0.35. Twenty-six percent of deaths (\( n=18 \)) occurred during follow-up of patients who had undergone AVR. Among the 52 patients who died before AVR, 33 (63%) had AT/ET >0.35. The 1-, 2-, and 3-year overall mortality rates under medical and/or surgical management were 6%, 11%, and 12% for patients with AT/ET \( \leq 0.35 \) and 11%, 17%, and 25% when AT/ET >0.35, respectively (\( P=0.009 \); Figure 4A). On multivariable analysis, AT/ET >0.35 was strongly associated with an increased risk of mortality compared with \( \leq 0.35 \) (adjusted HR, 2.34; 95% CI, 1.36–4.03; \( P=0.002 \)). After adjustment for AVR treated as a time-dependent covariate, patients with AT/ET >0.35 were at increased risk of death compared with those with AT/ET \( \leq 0.35 \) (adjusted HR, 2.54; 95% CI, 1.47–4.37; \( P<0.001 \); Figure 4B and Table 2). The performance of the multivariable models was verified by bootstrap resampling and 5-fold cross-validation (Table S2). When Vmax was replaced by MPG in the fully adjusted multivariable model, AT/ET >0.35 was still associated with increased mortality risk (adjusted HR, 2.58; 95% CI, 1.49–4.46; \( P<0.001 \)). When LV-SVi was replaced by
### Table 1. Demographic, Clinical, and Echocardiographic Parameters, Overall and According to AT/ET ≤0.35 and >0.35

| Variable                                             | All (N=353) | AT/ET ≤0.35 (n=183) | AT/ET >0.35 (n=170) | Overall P value |
|------------------------------------------------------|-------------|----------------------|----------------------|-----------------|
| Demographic and clinical characteristics             |             |                      |                      |                 |
| Age, y                                               | 79 (71 to 85) | 77 (68 to 84)        | 78 (70 to 84)        | 0.665           |
| Female sex, n (%)                                    | 163 (46)    | 80 (44)              | 83 (49)              | 0.393           |
| Body surface area, m²                                 | 1.86 (1.72 to 2.00) | 1.87 (1.69 to 2.00) | 1.86 (1.73 to 2.00) | 0.628           |
| BMI, kg/m²                                           | 27.1 (23.9 to 31.2) | 27.0 (23.9 to 30.8) | 27.3 (23.9 to 32.1) | 0.274           |
| SBP, mm Hg                                           | 140 (126 to 151) | 140 (130 to 156)     | 138 (120 to 150)     | 0.002           |
| DBP, mm Hg                                           | 73 (65 to 80) | 72 (64 to 80)        | 75 (67 to 80)        | 0.536           |
| Heart rate, bpm                                      | 75 (71 to 85) | 75 (71 to 85)        | 74 (66 to 84)        | 0.965           |
| Hypertension, n (%)                                  | 263 (74.5)  | 149 (46)             | 114 (67)             | 0.003           |
| Diabetes, n (%)                                      | 107 (30)    | 59 (32)              | 48 (28)              | 0.483           |
| Documented CAD, n (%)                                | 124 (35)    | 69 (38)              | 55 (32)              | 0.347           |
| History of AF, n (%)                                 | 86 (24)     | 50 (27)              | 36 (21)              | 0.222           |
| Use of β blockers, n (%)                             | 139 (39)    | 76 (41)              | 63 (37)              | 0.453           |
| Charlson comorbidity index                           | 1 (0 to 3)  | 1 (0 to 3)           | 1 (0 to 3)           | 0.573           |
| NYHA functional class I, n (%)                       | 147 (42)    | 84 (46)              | 63 (37)              | 0.115           |
| Echocardiographic parameters                         |             |                      |                      |                 |
| Aortic valve                                         |             |                      |                      |                 |
| AVA, cm²                                             | 0.76 (0.63 to 0.87) | 0.77 (0.67 to 0.90) | 0.74 (0.58 to 0.85) | 0.005           |
| AVAi, cm²/m²                                         | 0.41 (0.34 to 0.47) | 0.43 (0.37 to 0.48) | 0.39 (0.32 to 0.45) | <0.001          |
| Peak aortic jet velocity, m/s                       | 4.40 (4.18 to 4.80) | 4.35 (4.11 to 4.60) | 4.50 (4.20 to 5.00) | 0.001           |
| Mean pressure gradient, mm Hg                       | 49 (44 to 58) | 46 (42 to 52)        | 53 (45 to 64)        | <0.001          |
| Dimensionless index                                  | 0.20 (0.17 to 0.24) | 0.22 (0.19 to 0.24) | 0.19 (0.16 to 0.22) | <0.001          |
| Acceleration time, ms                                | 107 (93 to 122) | 96 (83 to 106)       | 120 (109 to 130)     | <0.001          |
| Ejection time, ms                                    | 305 (283 to 332) | 304 (277 to 332)     | 306 (287 to 333)     | 0.647           |
| AT/ET                                                | 0.35 (0.32 to 0.39) | 0.32 (0.30 to 0.34) | 0.39 (0.37 to 0.42) | By design        |
| Other parameters                                     |             |                      |                      |                 |
| AF during TTE, n (%)                                 | 31 (9)      | 19 (10)              | 12 (7)               | 0.361           |
| LV-EDD, mm                                           | 48 (43 to 52) | 47 (43 to 52)        | 48 (43 to 54)        | 0.361           |
| LV-ESD, mm                                           | 29 (26 to 34) | 29 (25.5 to 33)      | 30 (26 to 35)        | 0.114           |
| LV-SV, mL                                            | 80 (66 to 93) | 80 (68 to 91)        | 79 (65 to 95)        | 0.508           |
| LV-SVi, mL/m²                                       | 43 (37 to 50) | 44 (39 to 50)        | 42 (35 to 49)        | 0.082           |
| LV ejection fraction, %                              | 63 (60 to 68) | 64 (60 to 68.5)      | 63 (59 to 68)        | 0.020           |
| Flow rate, mL/s                                     | 260 (221 to 311) | 262 (226 to 312)     | 256 (212 to 302)     | 0.182           |
| GLS, % (N=244)                                        | −14.9 (−17.2 to −12) | −15.5 (−18 to −12.9) | −14.5 (−16.6 to −11) | 0.007           |
| RWT                                                  | 0.51 (0.43 to 0.61) | 0.50 (0.42 to 0.59) | 0.52 (0.44 to 0.63) | 0.062           |
| LVMI, g/m²                                           | 120 (99.2 to 146) | 117 (95.4 to 138)    | 128 (104 to 153)     | 0.004           |
| LAVi, mL/m²                                          | 41 (33 to 52) | 41 (32 to 51)        | 43 (34 to 54)        | 0.140           |
| E/A ratio                                            | 0.77 (0.63 to 1.01) | 0.77 (0.65 to 1.01) | 0.77 (0.63 to 1.01) | 0.682           |
| E/e’ ratio                                           | 8.94 (6.50 to 12.9) | 9.00 (7.00 to 12.4) | 8.50 (5.92 to 13.1) | 0.237           |
| PAPs, mm Hg (N=268)                                  | 35 (29 to 42) | 35 (29 to 41)        | 34.5 (30 to 42)      | 0.940           |
| TAPSE                                                | 22 (19 to 25) | 22 (19 to 26)        | 21 (18 to 25)        | 0.129           |

Continuous variables are presented as median (25th to 75th percentile). Categorical variables are presented as absolute numbers and frequency. A indicates mitral A wave velocity; AF, atrial fibrillation; AT/ET, ratio of acceleration time/ejection time; AVA, aortic valve area; AVAi, AVA indexed to body surface area; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; DBP, diastolic blood pressure; E, mitral E wave velocity; e’, early diastolic mitral annular velocity; GLS, global longitudinal strain; LAVi, left atrial volume indexed to body surface area; LV, left ventricular; LV-EDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; LVMI, LV mass indexed to body surface area; NYHA, New York Heart Association; PAPs, systolic pulmonary artery pressure; RWT, relative wall thickness; SBP, systolic blood pressure; SV, stroke volume; SVi, SV indexed to body surface area; TAPSE, tricuspid annular plane systolic excursion; and TTE, transthoracic echocardiography.
transaortic flow rate in the fully adjusted multivariable model, patients with AT/ET >0.35 still displayed an increased mortality risk compared with those with AT/ET ≤0.35 (adjusted HR, 2.55; 95% CI, 1.48–4.47; \( P < 0.001 \)). After further adjustment for GLS when available, AT/ET >0.35 was associated with increased risk of mortality (adjusted HR, 3.54; 95% CI, 1.67–7.49; \( P < 0.001 \)). When analysis was restricted to patients in sinus rhythm at time of examination (n=322), those with AT/ET >0.35 still displayed an increased mortality risk compared with those with AT/ET ≤0.35 (adjusted HR, 2.33; 95% CI, 1.31–4.15; \( P = 0.004 \)).

**Outcome With Conservative Management**

Median follow-up time under conservative management was 17 (25th–75th percentile, 7–37) months. Cumulative 1-, 2-, and 3-year overall mortality rates were 10%, 15%, and 20% for patients with AT/ET ≤0.35 and 16%, 31%, and 53% for patients with AT/ET >0.35, respectively (\( P = 0.001 \); Figure 5A). On multivariable analysis, after adjustment for age, sex, Charlson comorbidity index, SBP, history of AF, LVEF, Vmax, and LV-SVi, patients with AT/ET >0.35 exhibited a significantly greater risk of death compared with patients with AT/ET ≤0.35 (adjusted HR, 3.29; 95% CI, 1.70–6.39; \( P < 0.001 \); Figure 5B and Table 2). After further adjustment for GLS when available, AT/ET >0.35 remained strongly associated with an increased risk of mortality (adjusted HR, 4.30; 95% CI, 1.79–10.32; \( P = 0.001 \)).

**Incremental Prognostic Value of AT/ET**

As shown in Table 3, at 36 months, the addition of AT/ET >0.35 in contrast with AT/ET as a continuous variable (per increment of 0.01) to the multivariable models resulted in significant systematic improvement of 2 log-likelihood \( \chi^2 \), continuous net reclassification improvement, and integrated discrimination index when survival was considered either on medical or medical and/or surgical management, thereby demonstrating the incremental prognostic value of AT/ET >0.35 in this study population over established predictors of outcome in SAS.

**Subgroup Analyses**

Overall, the increased risk of mortality in patients with AT/ET >0.35 was consistent in subgroups of patients with high-gradient SAS and no or mild symptoms (Figure 6). No significant interaction was found between AT/ET >0.35 and any of the subgroups.

**Outcome Impact of AT/ET in the Propensity-Matched Cohort**

The baseline characteristics of covariates used for propensity matching before and after matching are shown in Table 4. Between-group balance was obtained for all matched covariates. A total of 117 patients with AT/ET >0.35 were matched to 117 patients with AT/ET ≤0.35. Median (25th–75th percentile) AT/ET was 0.32 (0.30–0.34) in patients with AT/ET ≤0.35 and 0.39 (0.37–0.40) in patients with AT/ET >0.35. Patients with AT/ET >0.35 displayed an increased mortality risk compared with those with AT/ET ≤0.35 (HR, 2.21; 95% CI, 1.16–4.20; \( P = 0.016 \)). After adjustment for AVR as a time-dependent covariate in this propensity-matched sample, AT/ET >0.35 still was associated with increased risk of mortality (adjusted HR, 2.10; 95% CI, 1.12–3.90; \( P < 0.001 \)).

**DISCUSSION**

The present study, based on a cohort of patients with high-gradient SAS, preserved LVEF, and no or only mild symptoms, provides strong evidence of the relationship between overall mortality and baseline AT/ET assessed by Doppler-echocardiography. Our results show that the effect of AT/ET on mortality is powerful...
and remains valid after adjustment for factors known as major determinants of outcome, such as age, comorbidity, SBP, LV ejection fraction, flow assessed by LV-SVi, Vmax, and AVR, during follow-up. We observed that AT/ET above the 0.35 cutoff is associated with a 2.5-fold increase in the risk of death during the entire follow-up (medical and/or surgical management) and with a 3.29-fold increased risk of death when survival under medical management was specifically considered. More important, AT/ET provided incremental prognostic information over established predictors of outcome in SAS, thereby suggesting that in clinical

**Figure 3.** Determination of the optimal ratio of acceleration time/ejection time (AT/ET) threshold for mortality using the maximally selected rank statistics. The dashed line demarcates the optimal AT/ET threshold: 0.35.

**Figure 4.** Survival analysis according to ratio of acceleration time/ejection time (AT/ET) ≤0.35 or >0.35 in patients with high-gradient severe aortic stenosis and no or mild symptoms under medical or surgical management (n=353).

A, Kaplan-Meier estimates of overall mortality. B, Adjusted mortality. Survival Cox curves are adjusted for age, sex, Charlson comorbidity index (not including age), systolic blood pressure, history of atrial fibrillation, left ventricular ejection fraction, aortic peak jet velocity, left ventricular stroke volume index, and aortic valve replacement as a time-dependent covariate. HR indicates hazard ratio.
The concept of delayed aortic AT associated with worsening AS severity is not new. Indeed, previous landmark reports have observed a good correlation between AT/ET and invasive measurement of transaortic pressure gradients. Rapid early-systolic opening of the normal aortic valve on Doppler spectrograms is replaced by a slow end-systolic opening of the stenotic aortic valve. Alongside with this, although LV ET usually increases when AS is present, it may normalize in patients presenting with LV dysfunction or low flow. Accordingly, guidelines already suggest that the aortic waveform shape could be useful to assess severity of native AS. Calculation of AT/ET ratio provides reproducible quantification of this well-known phenomenon. Moreover, the AT/ET ratio, in contrast to AT or ET taken aside, is not influenced by heart rate. We previously reported an association between AT/ET ratio >0.34 and SAS in a large multicenter cohort of patients with mild to severe AS. However, the reported correlations between AT/ET and parameters of AS severity, such as transvalvular gradient or AVA, obtained by Doppler echocardiography were only moderate. Accordingly, weak positive correlations were observed between AT/ET and transaortic mean gradient or Vmax in the present study. Indeed, the AT/ET ratio is not only associated with AS severity but also with its consequences on the LV. In a multicenter study involving 1107 patients with AS, decreased LVEF, decreased LV-SVi, increased LV mass index and relative wall thickness were independently associated with an increased AT/ET ratio. On the basis of data from the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study, Einarsen et al similarly reported an independent relationship between higher AT/ET ratio and determinants of LV morphology and function, as mentioned above. In the present study population, patients with greater AT/ET actually displayed lower LV ejection fraction or GLS magnitude. In a similar way, an inverse relationship between SBP and AT/ET has been previously reported. In the presence of arterial stiffness, reflected waves display greater magnitude and higher propagation speed, thereby arriving earlier at the LV outflow tract than those with compliant aorta. This may lead to shorten AT because of early aortic flow deceleration. Furthermore, the increase in afterload associated with higher SBP is likely to induce compensatory lengthening of systolic ET, thereby reducing the AT/ET ratio. These potential confounding factors may explain why, for a given transaortic mean gradient, the AT/ET ratio can significantly differ from one patient to another. Herein, a wide range for AT/ET values was actually observed, despite the relatively similar phenotype of the patients from the present report with high-gradient SAS. In other words, a large number of patients diagnosed with high-gradient SAS can anyway present with short AT/ET. Thus, the question of whether patients with longer AT/ET ratios could share worse outcome compared with those with shorter ones may be raised.

To date, the clinical implications of AT/ET in the setting of native AS have been investigated only in patients presenting with discordant grading (ie, with low-gradient AS despite a narrow stenotic orifice) or in heterogeneous study populations mixing moderate and severe AS regardless of their symptomatic status. The present study builds on previous literature by focusing on the specific population of high-gradient

---

**Table 2. Relative Risk of All-Cause Mortality, According to AT/ET**

| Variable | All-cause mortality | HR (95% CI) | P value |
|----------|---------------------|-------------|---------|
| Univariate analysis | AT/ET per increment of 0.01 | 1.09 (1.04–1.16) | <0.001 |
| | AT/ET ≤0.35 | Reference | |
| | AT/ET >0.35 | 2.44 (1.39–4.29) | <0.001 |
| Multivariable model (n=230)* | AT/ET per increment of 0.01 | 1.11 (1.04–1.18) | 0.002 |
| | AT/ET ≤0.35 | Reference | |
| | AT/ET >0.35 | 3.29 (1.70–6.39) | <0.001 |
| Outcome under medical and/or surgical management | Univariate analysis | AT/ET per increment of 0.01 | 1.06 (1.01–1.11) | 0.018 |
| | AT/ET ≤0.35 | Reference | |
| | AT/ET >0.35 | 1.89 (1.16–3.03) | 0.010 |
| Multivariable model without AVR (n=347)* | AT/ET per increment of 0.01 | 1.08 (1.02–1.14) | 0.009 |
| | AT/ET ≤0.35 | Reference | |
| | AT/ET >0.35 | 2.34 (1.36–4.03) | 0.002 |
| Multivariable model with AVR (n=347)* | AT/ET per increment of 0.01 | 1.09 (1.03–1.15) | 0.004 |
| | AT/ET ≤0.35 | Reference | |
| | AT/ET >0.35 | 2.54 (1.47–4.37) | <0.001 |

AT/ET indicates ratio of acceleration time/ejection time; AVR, aortic valve replacement; and HR, hazard ratio.

*Multivariable model is adjusted for age, sex, systolic blood pressure, Charlson comorbidity index (without including age), history of atrial fibrillation, peak aortic jet velocity, left ventricular stroke volume index, and left ventricular ejection fraction.

†Model is adjusted for covariates included in the model without AVR and AVR as time-dependent covariate.

---

AT/ET in Severe Aortic Stenosis

J Am Heart Assoc. 2021;10:e021873. DOI: 10.1161/JAHA.121.021873
SAS with no or only mild symptoms. The results of this report expand previous findings by demonstrating, in these challenging high-risk patients, an incremental prognostic value of AT/ET over known features strongly linked with adverse outcome in SAS in both multivariable and propensity-matched analyses. More important, the relationship between increased AT/ET and mortality remained significant even after adjustment for LV ejection fraction, flow, SBP, or GLS, all previously suggested as potential confounders for AT/ET, thereby strengthening the clinical significance of this parameter. The finding that baseline AT/ET predicts mortality independently from AVR if LV function is preserved may be questioning. Multiple intricate factors account for AT/ET values in patients with preserved LVEF, including LV remodeling and function, AS severity, and SBP. Hence, increased AT/ET identifies patients with SAS and preserved LVEF at a more advanced stage of the disease, thereby explaining that an increased risk of mortality persists for increased AT/ET values, even after adjustment on AVR.

In addition, we did not purposefully use a combined end point associating mortality and valve intervention because the referral for AVR is potentially related to the

Table 3. Predictive Value, Discrimination, and Reclassification of the Cox Multivariable Models With and Without AT/ET on Overall Mortality

| Overall mortality | Models | Log-likelihood \( \chi^2 \) | \( P \) value | Continuous NRI | \( P \) value | Integrated discrimination index | \( P \) value |
|-------------------|--------|----------------|----------------|----------------|----------------|-------------------------------|----------------|
| Outcome under conservative management (n=230) | Multivariable model | 49.25 | Reference | | | Reference | Reference |
| | +AT/ET >0.35 | 62.69 | <0.001 | 0.35 | 0.033 | 0.09 | 0.013 |
| | +AT/ET per increment of 0.01 | 59.31 | 0.001 | 0.30 | 0.106 | 0.07 | 0.033 |
| Outcome under medical and/or surgical management (n=347) | Multivariable model without AVR* | 90.7 | Reference | | | Reference | Reference |
| | +AT/ET >0.35 | 100.5 | 0.002 | 0.20 | 0.027 | 0.03 | 0.040 |
| | +AT/ET per increment of 0.01 | 97.57 | 0.009 | 0.12 | 0.326 | 0.02 | 0.086 |
| | Multivariable model with AVR† | 108 | Reference | | | Reference | Reference |
| | +AT/ET >0.35 | 120 | <0.001 | 0.23 | <0.001 | 0.04 | 0.020 |
| | +AT/ET per increment of 0.01 | 116.6 | 0.003 | 0.23 | 0.126 | 0.03 | 0.053 |

AT/ET indicates ratio of acceleration time/ejection time; AVR, aortic valve replacement; and NRI, net reclassification improvement.

*Multivariable model is adjusted for age, sex, systolic blood pressure, Charlson comorbidity index (without including age), history of atrial fibrillation, peak aortic jet velocity, left ventricular stroke volume index, and left ventricular ejection fraction.

†Model is adjusted for covariates included in the model without AVR and AVR as time-dependent covariate.
Altes et al AT/ET in Severe Aortic Stenosis

personal physician’s assessment of disease severity and consequences. Thus, the present data provide a clear prognostic cutoff value for AT/ET (>0.35) associated with overall mortality. Indeed, previous reports have suggested different cutoffs for AT/ET (0.32–0.37) as these study populations involved displayed significant differences (inclusion of patients with mild, moderate, and/or discordant grading AS). Of note, an optimal cut-off for AT/ET of 0.35 was found to identify patients with SAS in a previous independent study.11 Hence, we suggest herein that a unique 0.35 threshold may be useful in daily clinical cardiology practice in asymptomatic SAS.

This study has limitations. First, although echocardiograms were prospectively collected, follow-up was retrospectively obtained. The specific indications for AVR during follow-up were not recorded in our database. However, diagnosis and follow-up were performed by cardiologists with expertise in valvular heart disease, and surgical decisions were taken by the heart team with the approval of the patient’s physician in accordance with current practice guidelines. Serum biomarkers were not routinely assessed in this patient population. The present study includes a “real-world” population of patients with SAS and no

| Hazard Ratio (HR) and 95% CI for risk of overall mortality associated with ratio of acceleration time/ejection time ≤0.35 or >0.35 in subgroups of patients with high-gradient severe aortic stenosis and no or mild symptoms. |
| AF indicates atrial fibrillation; AVA, aortic valve area; BSA, body surface area; CAD, coronary artery disease; LV, left ventricular; LVEF, LV ejection fraction; LVH, LV hypertrophy; MPG, mean aortic pressure gradient; NYHA, New York Heart Association; SVI, stroke volume index; and Vmax, aortic peak jet velocity. |

| HR (95% CI), P | P for interaction |
|---|---|
| Age ≤ 80 years (n=218, 62%) | 2.82 (1.05,7.58), P=0.040 | 0.505 |
| Age > 80 years (n=135, 38%) | 2.07 (1.17,3.67), P=0.012 | |
| Male (n=190, 54%) | 2.58 (1.18,5.67), P=0.018 | 0.361 |
| Female (n=183, 46%) | 1.95 (1.03,3.70), P=0.040 | |
| BSA ≤ 1.80 m² (n=133, 38%) | 1.98 (1.05,3.74), P=0.034 | 0.632 |
| BSA > 1.80 m² (n=220, 62%) | 2.56 (1.17,5.69), P=0.019 | |
| NYHA class I (n=147, 42%) | 2.31 (1.13,4.73), P=0.022 | 0.821 |
| NYHA class II (n=206, 58%) | 2.07 (1.05,4.07), P=0.035 | |
| No history of AF (n=267, 76%) | 2.47 (1.32,4.64), P=0.005 | 0.971 |
| History of AF (n=86, 24%) | 2.47 (1.07,5.68), P=0.033 | |
| No documented CAD (n=229, 75%) | 2.13 (1.14,3.98), P=0.018 | 0.610 |
| Documented CAD (n=124, 35%) | 2.57 (1.13,5.85), P=0.024 | |
| Vmax < 5 m/s (n=280, 79%) | 2.22 (1.31,3.77), P=0.003 | 0.721 |
| Vmax ≥ 5 m/s (n=73, 21%) | 2.77 (0.60,12.90), P=0.194 | |
| MPG < 50 mmHg (n=187, 53%) | 1.88 (1.05,3.38), P=0.035 | 0.208 |
| MPG ≥ 50 mmHg (n=166, 47%) | 4.84 (1.64,14.29), P=0.004 | |
| AVA ≥ 0.75 cm² (n=191, 54%) | 2.10 (0.98,4.49), P=0.056 | 0.726 |
| AVA < 0.75 cm² (n=162, 46%) | 1.97 (1.04,3.76), P=0.039 | |
| LVEF > 60% (n=236, 67%) | 2.01 (1.10,3.69), P=0.023 | 0.548 |
| LVEF ≤ 60% (n=118, 33%) | 3.17 (1.29,7.83), P=0.012 | |
| LV SVI > 35 ml/m² (n=279, 79%) | 1.93 (1.09,3.44), P=0.025 | 0.511 |
| LV SVI ≤ 35 ml/m² (n=74, 21%) | 2.96 (0.99,8.64), P=0.052 | |
| No LVH (n=120, 66%) | 2.51 (1.06,5.94), P=0.036 | 0.516 |
| LVH (n=233, 24%) | 1.94 (1.07,3.53), P=0.029 | |

J Am Heart Assoc. 2021;10:e021873. DOI: 10.1161/JAHA.121.021873
or mild symptoms, in whom exercise testing was not systematically performed. Hence, we cannot assess if baseline AT/ET correlated with exercise tolerance.

However, patients with SAS, especially those with older ages, often present with comorbidities, impaired physical mobility, or self-restrictions in their

| Table 4. Baseline Characteristics, According to AT/ET >0.35 and ≤0.35, Before and After Propensity Score Matching |
|---|---|---|---|---|---|---|
| Covariates | AT/ET ≤0.35 (N=183) | AT/ET >0.35 (N=170) | SMD | AT/ET ≤0.35 (N=117) | AT/ET >0.35 (N=117) | SMD |
| Age, y | 76±11 | 76±11 | 0.025 | 75±11 | 75±12 | 0.057 |
| Women, n (%) | 80 (44) | 83 (49) | 0.103 | 59 (50) | 51 (44) | 0.068 |
| Charlson comorbidity index | 1.6±1.9 | 1.7±1.6 | 0.014 | 1.8±2 | 1.7±1.6 | 0.047 |
| History of AF | 50 (27) | 36 (21) | 0.144 | 34 (29) | 28 (24) | 0.051 |
| Systolic blood pressure, mm Hg | 143±21 | 136±19 | 0.360 | 140±19 | 140±17 | 0.054 |
| NYHA class I | 84 (46) | 63 (37) | 0.180 | 50 (43) | 50 (43) | <0.001 |
| Peak aortic jet velocity, m/s | 4.48±0.44 | 4.64±0.52 | 0.375 | 4.52±0.48 | 4.55±0.46 | 0.049 |
| Aortic valve area, cm² | 0.78±0.17 | 0.73±0.19 | 0.269 | 0.76±0.17 | 0.76±0.20 | 0.024 |
| LV ejection fraction, % | 63±7 | 63±6 | 0.260 | 63±6 | 63±6 | 0.028 |
| LV mass index, g/m² | 118±36 | 131±40 | 0.327 | 123±37 | 130±38 | 0.17 |

SMDs are reported for the entire cohort and the matched cohort. SMDs <0.2 after matching were considered as indicators of adequate balance and thus sufficient bias reduction. Continuous variables are presented as means±SD. Categorical variables are presented as absolute numbers and frequency. AF indicates atrial fibrillation; AT/ET, ratio of acceleration time/ejection time; LV, left ventricular; NYHA, New York Heart Association; SMD, standardized mean difference; and SVi, stroke volume indexed to body surface area.
daily activities. In such patients, exercise testing may not be feasible or may lack specificity.\textsuperscript{38,39} Cardiac magnetic resonance imaging was not available in the vast majority of the study population. Hence, we cannot provide data on LV myocardial fibrosis. The results of this study cannot apply in patients with AF at time of echocardiography because of the small sample size of this subset of patients (n=31). We used propensity-matching analysis to strengthen the results of the present report. This analysis allows finding the similarity between patients on every observable characteristic included in the propensity score, given they were presenting with AT/ET >0.35 or ≤0.35. Therefore, propensity scoring ensures that the distribution of characteristics constituting the score, known as both predictors of outcome in SAS and possible modifying factors of AT/ET, was equivalent for the 2 groups of patients. However, propensity-matching analysis only accounts for identified covariates (those included in the score).\textsuperscript{40} Hence, some imbalances may have remained between the 2 groups because of some unreported confounders associated with AT/ET >0.35 or ≤0.35. Then, the use of 1:1 nearest-neighbor matching algorithm allowed us to reduce selection bias by taking the most similar patient from one group compared with one from the other but leading to a reduced sample size. Even so, a 2.5-fold increased mortality risk for AT/ET >0.35 was observed in the propensity-matched sample, similar to the results in the whole study population, thereby strengthening the validity of this analysis. The data on AT/ET after AVR were not available in our database. The results of the present study cannot apply for patients with LV dysfunction (LVEF <50%) or those with significant valve regurgitation. Whether assessment of AT/ET may be associated with adverse outcome in patients with low-gradient AS and low LVEF needs further research. Finally, future studies should be conducted to externally validate the impact of AT/ET with a threshold value of 0.35 on adverse outcome and determine whether assessment of AT/ET should be integrated in the decision-making process in patients with SAS and preserved LVEF.

**CONCLUSIONS**

This study, based on a registry of patients with high-gradient SAS, preserved LV ejection fraction, and no or only mild symptoms managed in routine clinical practice, shows that AT/ET is a reliable parameter to predict mortality, with a threshold value of 0.35, beyond established prognostic factors in SAS. Our findings suggest that assessment of AT/ET should be integrated in the decision-making process in patients with SAS and preserved LVEF.

**REFERENCES**

1. Baumgartner H, Jung B, Otto CM. Timing of intervention in asymptomatic patients with valvular heart disease. *Eur Heart J*. 2020;41:4349–4356. doi: 10.1093/eurheartj/ehaa485

2. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, et al. ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739–2791. doi: 10.1093/eurheartj/ehx391

3. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP III, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143:e72–e227. doi: 10.1161/CIR.0000000000000923

4. Thellier N, Altes A, Appert L, Binda C, Lancellotti P, McLeod C, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143:e72–e227. doi: 10.1161/CIR.0000000000000923

5. Maréchaux S, Rusinaru D, Altes A, Pasquet A, Vanoverschelde JL, Tribouilloy C. Prognostic value of low flow in patients with high transvalvular gradient severe aortic stenosis and preserved left ventricular ejection fraction: a multicenter study. *Circ Cardiovasc Imaging*. 2019;12:e009299. doi: 10.1161/CIRCIMAGING.119.009299

6. Maréchaux S, Tribouilloy C. Acceleration time in aortic stenosis: a new life for an old parameter. *Circ Cardiovasc Imaging*. 2014;7:1223–12234. doi: 10.1161/CIRCIMAGING.120.012234

7. Altes A, Sochala M, Attias D, Dreyfus J, Bobbot Y, Toledano M, Macron N, Renard C, Chadha G, Truffer A, et al. Correlates of the ratio of acceleration time to ejection time in patients with aortic stenosis: an echocardiographic and computed tomography study. *Arch Cardiovasc Dis*. 2019;112:567–575. doi: 10.1016/j.acvd.2019.06.004

8. Gamaza-Chulán S, Camacho-Freire S, Toro-Cebada R, Giráldez-Valpuesta A, Benezet-Mazuecos J, Vargas-Machuca JC. Ratio of acceleration time to ejection time for assessing aortic stenosis severity. *Echocardiography*. 2015;32:1754–1761. doi: 10.1111/eco.12978

9. Ringle Griguer A, Tribouilloy C, Truffer A, Castel A-L, Deléses F, Levy F, Vincentelli A, Bobbot Y, Maréchaux S. Clinical significance of ejection dynamics parameters in patients with aortic stenosis: an outcome study. *J Am Soc Echocardiogr*. 2018;31:551–560.e552. doi: 10.1016/j.echo.2017.11.015

10. Altes A, Thellier N, Bobbot Y, Marsou W, Chadha G, Binda C, Ringle A, Maillet A, Marotte N, Riolet C, et al. Prognostic impact of the ratio of acceleration time to ejection time in patients with low gradient severe aortic stenosis and preserved ejection fraction. *Am J Cardiol*. 2019;124:1594–1600. doi: 10.1016/j.amjcard.2019.07.064
11. Gamaza-Chulian S, Diaz-Retameno E, Camacho-Freire S, Ruiz-Fernandez D, Gutierrez-Barrios A, Oneto-Otero J. Acceleration time and ratio of acceleration time to ejection time in aortic stenosis: new echocardiographic diagnostic parameters. J Am Soc Echocardiogr. 2017;30:947–955. doi: 10.1016/j.echo.2017.06.001

12. Enarnes E, Cramariuc D, Bahlmann E, Middibo H, Chambers JB, Gerots E. Higher acceleration/ejection time ratio predicts impaired outcome in aortic valve stenosis. Circ Cardiovasc Imaging. 2021;14:e011467. doi: 10.1161/CIRCIMAGING.120.011467

13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8

14. Namasivayam M, He W, Churchill TW, Capoulaide R, Liu S, Lee H, Dank JS, Picard MH, Pibarat P, Levine RA, et al. Transvalvular flow rate determines prognostic value of aortic valve area in aortic stenosis. J Am Coll Cardiol. 2020;75:1758–1769. doi: 10.1016/j.jacc.2020.02.046

15. Tastet L, Tribouilloy C, Maréchaux S, Vollema EM, Delgado V, Salaun E, Shen M, Capoulaide R, Clavel M-A, Aresnault M, et al. Staging cardiac damage in patients with asymptomatic aortic valve stenosis. J Am Coll Cardiol. 2019;74:550–563. doi: 10.1016/j.jacc.2019.04.065

16. Hothorn T. maxstat: maximally selected rank statistics. R package version 0.7-25. https://CRAN.R-project.org/package=maxstat. Accessed March 1, 2001.

17. Therneau T. A package for survival analysis in R. R package version 3.2-13. Available at: https://CRAN.R-project.org/package=survival. Accessed August 23, 2021.

18. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Ann Rev Public Health. 1999;20:145–157. doi: 10.1146/annurev.publhealth.20.1.145

19. Canty A & Ripley B. boot: bootstrap R (S-Plus) functions. R package version 1.3-28. Available at: https://CRAN.R-project.org/package=boot. Accessed April 16, 2021.

20. Uno H, Cai T. survIDINRI: IDI and NRI for comparing competing risk models with censored survival data. R package version 1.1-1. Available at: https://CRAN.R-project.org/package=survIDINRI. Accessed April 08, 2013.

21. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1–28. https://www.jstatsoft.org/v42/i08/

22. Clavel MA, Mallet J, Michielena HI, Suri RM, Jaffee AS, Mahoney DW, Enriquez-Sarano M. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol. 2014;63:2016–2025. doi: 10.1016/j.jacc.2014.02.581

23. Bobbot Y, de Meester de Ravenstein C, Chadha G, Rusinaru D, Belkhir K, Trouillet C, Pasquiel A, Maréchaux S, Vanoverschelde JL, Tribouilloy C. Relationship between left ventricular ejection fraction and mortality in asymptomatic and minimally symptomatic patients with severe aortic stenosis. JACC Cardiovasc Imaging. 2019;12:38–48. doi: 10.1016/j.jcmg.2018.07.029

24. Rosenhek R, Binder T, Poreta G, Lang I, Christ G, Scheper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–617. doi: 10.1056/NEJM200008313430903

25. Bobbot Y, Kowalski C, Rusinaru D, Ringle A, Maréchaux S, Tribouilloy C. Impact of mean transaortic pressure gradient on long-term outcome in patients with severe aortic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc. 2017;6:e005850. doi: 10.1161/ JAHA.117.005850

26. Rusinaru D, Bobbot Y, Kowalski C, Ringle A, Maréchaux S, Tribouilloy C. Left atrial volume and mortality in patients with aortic stenosis. J Am Heart Assoc. 2017;6:e006615. doi: 10.1161/JAHA.117.006615

27. Bobbot Y, Rusinaru D, Delpiere Q, Maréchaux S, Tribouilloy C. Risk stratification of severe aortic stenosis with preserved left ventricular ejection fraction using peak aortic jet velocity: an outcome study. Circ Cardiovasc Imaging. 2017;10:e006760. doi: 10.1161/CIRCIMAGING.117.006760

28. Kamimura D, Hans S, Suzuki T, Fox ER, Hall ME, Musani SK, McMullan MR, Little WC. Delayed time to peak velocity is useful for detecting severe aortic stenosis. J Am Heart Assoc. 2016;5:e003907. doi: 10.1161/ JAHA.116.003907

29. Kim SH, Kim JS, Kim BS, Choi J, Lee SC, Oh JK, Park SW. Time to peak velocity of aortic flow is useful in predicting severe aortic stenosis. Int J Cardiol. 2014;172:e443–e446. doi: 10.1016/j.ijcard.2013.12.318

30. Hatle L, Angelsen BA, Tromsdal A. Non-invasive assessment of aortic stenosis by doppler ultrasound. Br Heart J. 1980;43:284–292. doi: 10.1136/hrt.43.3.284

31. Agastson AS, Chengot M, Rao A, Hildner F, Samet P. Doppler diagnosis of valvular aortic stenosis in patients over 60 years of age. Am J Cardiol. 1985;56:106–109. doi: 10.1016/0002-9149(85)90075-2

32. Bermejo J, Antoranz JC, Garcia-Fernández MA, Moreno MM, Delcán JL. Flow dynamics of stenotic aortic valves assessed by signal processing of Doppler spectra. Am J Cardiol. 2000;85:611–617. doi: 10.1016/S0002-9149(99)00820-6

33. Reant P, Dijos M, Donal E, Mignot A, Ritter P, Bordachar P, Dos Santos P, Leclercq C, Roudaut R, Habib G, et al. Systolic time intervals as simple echocardiographic parameters of left ventricular systolic performance: correlation with ejection fraction and longitudinal two-dimensional strain. Eur J Echocardiogr. 2010;11:834–844. doi: 10.1093/ejecho/jep084

34. Biering-Sørensen T, Querejeta Roca G, Hegde SM, Shah AM, Claggett B, Mosley TH Jr, Butler KR Jr, Solomon SD. Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. Eur Heart J. 2018;20:1106–1114. doi: 10.1002/ ejh.928

35. Bache RJ, Wang Y, Greenfield JC Jr. Left ventricular ejection time in valvular aortic stenosis. Circulation. 1973;47:527–533. doi: 10.1161/01.CIR.47.3.527

36. Kligfield P, Okin P. Effect of ventricular function on left ventricular ejection time in aortic stenosis. Br Heart J. 1979;42:438–441. doi: 10.1136/hrt.42.4.438

37. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edwardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F Jr, Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1156–1169. doi: 10.1016/j.echo.2017.02.009

38. Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, De Bonis M, Tribouilloy C, Evangelista A, et al; EORP VHD II Investigators. Contemporary presentation and management of valvular heart disease: the EURObservational Research Programme Valvular Heart Disease II Survey. Circulation. 2019;140:1156–1169. doi: 10.1161/CIRCULATIONAHA.119.041080

39. Zibberszcz R, Gabriell H, Scheper M, Lauffer G, Maurer G, Rosenhek R. Asymptomatic severe aortic stenosis in the elderly. JACC Cardiovasc Imaging. 2017;10:43–50. doi: 10.1016/j.jcmg.2016.05.015

40. Sainani KL. Propensity scores: uses and limitations. PM R. 2012;4:693–697. doi: 10.1016/j.pmrj.2012.07.002

J Am Heart Assoc. 2021;10:e021873. DOI: 10.1161/JAHA.121.021873
Supplemental Material
Table S1. Demographic, clinical and echocardiographic parameters in the subpopulation of patients who underwent aortic valve replacement (SAVR versus TAVR).

| Variable                              | All N = 238 | SAVR n = 154 | TAVR n = 84 | Overall p-value |
|---------------------------------------|-------------|--------------|-------------|----------------|
| Demographic and clinical characteristics |             |              |             |                |
| Age, years                            | 75 [67;82]  | 71 [63;77]   | 83 [79;87]  | <0.001         |
| Female sex, n (%)                     | 103 (43)    | 63 (41)      | 40 (48)     | 0.389          |
| Body surface area, m²                 | 1.89 [1.73;2.03] | 1.94 [1.81;2.08] | 1.81 [1.68;1.92] | <0.001        |
| BMI, kg/m²                            | 27.8 [24.4;32.3] | 28.9 [24.9;32.3] | 26.9 [23.9;30.1] | 0.012         |
| SBP, mmHg                             | 140 [128;151] | 140 [124;150] | 140 [130;151] | 0.367          |
| DBP, mmHg                             | 73 [64;80]  | 75 [63;80]   | 70 [65;80]  | 0.049          |
| Heart rate, bpm                       | 73 [65;83]  | 75 [67;84]   | 70 [61;80]  | 0.023          |
| Hypertension, n (%)                   | 177 (74)    | 106 (69)     | 71 (84)     | 0.013          |
| Diabetes mellitus, n (%)              | 69 (29)     | 49 (32)      | 20 (24)     | 0.249          |
| Documented CAD, n (%)                 | 99 (42)     | 62 (40)      | 37 (44)     | 0.668          |
| History of AF, n (%)                  | 55 (23)     | 31 (20)      | 24 (29)     | 0.188          |
| Use of beta-blockers, n (%)           | 104 (44)    | 61 (40)      | 43 (51)     | 0.113          |
| Charlson comorbidity index            | 1 [0;2]     | 1 [0;2]      | 2 [0;3]     | 0.002          |
| NYHA functional class I, n (%)        | 86 (36)     | 65 (42)      | 21 (25)     | 0.012          |
| Echocardiographic parameters          |             |              |             |                |
| Aortic valve                          |             |              |             |                |
| AVA, cm²                              | 0.76 [0.65;0.87] | 0.76 [0.65;0.90] | 0.76 [0.65;0.86] | 0.640          |
| AVAi cm²/m²                           | 0.41 [0.34;0.47] | 0.40 [0.34;0.46] | 0.43 [0.36;0.47] | 0.101          |
| Peak aortic jet velocity, m/sec       | 4.50 [4.20;4.95] | 4.45 [4.20;4.95] | 4.50 [4.20;4.93] | 0.406          |
| Mean pressure gradient, mm Hg         | 51 [44;62]  | 49.5 [45;62] | 52 [45;64]  | 0.456          |
| Dimensionless index                   | 0.20 [0.17;0.24] | 0.21 [0.17;0.24] | 0.20 [0.18;0.23] | 0.592          |
| Acceleration time, ms                | 110 [95;124] | 108 [93;121] | 116 [101;130] | 0.016          |
| Ejection time, ms                     | 309 [286;335] | 300 [277;329] | 325 [300;350] | <0.001         |
| AT/ET                                 | 0.35 [0.33;0.39] | 0.35 [0.32;0.39] | 0.36 [0.33;0.39] | 0.548          |
| Other parameters                      |             |              |             |                |
| AF during TTE                         | 21 (9)      | 8 (5)        | 13 (15)     | 0.015          |
| LVEDD, mm                             | 49 [43;54]  | 48 [43;54]   | 50 [44;54]  | 0.406          |
| LVESD, mm                             | 30 [26;34]  | 29 [26;33]   | 31 [26;35]  | 0.158          |
| LV-SV, ml                             | 81 [69;100] | 81 [68;95]   | 83.5 [70;101] | 0.294         |
| LV-SVi, ml/m²                         | 44 [37;52]  | 42 [36;49]   | 46 [41;55]  | 0.002          |
| LV ejection fraction, %               | 64 [60;68]  | 64.5 [60;69] | 63 [60;66]  | 0.139          |
| Flow rate (ml/s)                      | 266 [229;319] | 268 [230;329] | 261 [229;314] | 0.394          |
| GLS, % (N=194)                        | -15.2 [-17.3;-12.8] | -15.5 [-18;-13.5] | -14.3 [-15.9;-11.1] | 0.013          |
| RWT                                   | 0.48 [0.42;0.59] | 0.50 [0.42;0.59] | 0.47 [0.40;0.55] | 0.222          |
| LVMI, g/m²                            | 125 [104;152] | 122 [98;148] | 134 [112;161] | 0.042          |
| LAWi, ml/m²                           | 40 [33;51]  | 39 [30;50]   | 45 [38;55]  | 0.001          |
| E/A ratio                             | 0.77 [0.64;0.98] | 0.78 [0.65;1.00] | 0.75 [0.61;0.88] | 0.160          |
| E/e' ratio                            | 9 [6.50;13]  | 8.57 [6.25;11.6] | 11.5 [7.65;16.1] | <0.001         |
| PAPs, mmHg (N=266)                    | 33 [29;42]  | 33 [29;38]   | 36 [30;46]  | 0.021          |
| TAPSE                                 | 22 [19;26]  | 23 [19;26]   | 21 [18;24.5] | 0.031          |

Continuous variables are presented as median [interquartile range]. Categorical variables are presented as absolutes numbers and frequency. AF = atrial fibrillation; AT/ET = ratio of acceleration time to ejection time; AVA = aortic valve area; AVAi = aortic valve area indexed to body surface area; BMI = body mass index; CAD = coronary artery disease; DBP = diastolic blood pressure; EDD = end diastolic diameter; ESD = end systolic diameter, GLS = global...
longitudinal strain; LAVi = left atrial volume indexed to body surface area; LV = left ventricular; PAPs = systolic pulmonary artery pressure; SVi: stroke volume indexed to body surface area; Mi = mass indexed to body surface area; RWT = relative wall thickness; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement, SBP = systolic blood pressure; TAPSE = tricuspid annular plane systolic excursion; TTE = transthoracic echocardiography
Table S2. Performance of the multivariable models in the original sample, after bootstrap re-sampling (1000 times) and after cross-validation.

| Harrell's C-statistic | Multivariable model under medical management* (n=230) | Multivariable model under medical and/or surgical management without AVR* (n=347) | Multivariable model under medical and/or surgical management with AVR† (n=347) |
|-----------------------|------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Original sample       | 0.81                                                 | 0.82                                                                            | 0.82                                                                            |
| After bootstrap re-sampling | 0.83                                             | 0.83                                                                            | 0.84                                                                            |
| After cross-validation | 0.77                                                 | 0.80                                                                            | 0.80                                                                            |

| Adjusted HR (CI 95%) for AT/ET > 0.35 | Original sample | After bootstrap re-sampling |
|-------------------------------------|-----------------|-----------------------------|
| Original sample                     | 3.29 (1.70, 6.39) | 2.34 (1.36, 4.03)           |
| After bootstrap re-sampling         | 3.38 (1.55, 8.32) | 2.32 (1.26, 4.28)           |
|                                     | 2.54 (1.47, 4.37) | 2.58 (1.47, 4.79)           |

AVR, aortic valve replacement; CI, confidence interval; HR, hazard ratio; AT/ET: ratio of acceleration time to ejection time

*Multivariable model is adjusted for age, sex, systolic blood pressure, Charlson comorbidity index (without including age), history of atrial fibrillation, peak aortic jet velocity, left ventricular stroke volume index and left ventricular ejection fraction

†Model is adjusted for covariates included in the model without AVR and AVR as time-dependent covariate
Figure S1. Distribution of AT (A), ET (B) and AT/ET (C) measurements according to AT/ET ≤ or > 0.35
